Monitoring the efficacy of conservative treatment of nasopharyngeal carcinoma by examining Epstein–Barr virus DNA titers in blood plasma (review)
https://doi.org/10.17650/2222-1468-2020-10-3-81-89
Abstract
One of the main problems of nasopharyngeal carcinoma treatment is the high incidence regional and distant failures. The method of choice in the first line therapy for the primarily diagnosed nasopharyngeal carcinoma is chemoradiotherapy with poor success rate. The main etiological factor in the occurrence of nasopharyngeal carcinoma is the Epstein–Barr virus, which DNA’s copies could be detected in blood samples in patients with nasopharyngeal carcinoma, which may indicate tumor activity. The indicators of these titers reach different values depending on the stage of the tumor process, the presence of distant metastases, individual patient parameters, and the tumor response to the therapy. Given the high specificity of this biological marker, it is necessary to consider the possibility of its use as a prognostic indicator for assessing the success of the selected method of conservative treatment, as well as assessing the prognosis.
About the Authors
D. A. Miroshnichenko
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Bld. 4, 2 Bolshaya Pirogovskaya St., Moscow 119991
A. P. Polyakov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia;
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
Russian Federation
Bld. 4, 2 Bolshaya Pirogovskaya St., Moscow 119991,
32 nd Botkinsky Dr., Moscow 125284
A. V. Mordovsky
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
Russian Federation
32 nd Botkinsky Dr., Moscow 125284
References
1. Paches A.I., Brzhezovskyi V.Z., Demidov L.V. et al. Head and neck tumors: manual. Moscow: Prakticheskaya medicina, 2013. 478 p. (In Russ.).
2. Jemal A., Bray F., Center M.M. et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90. DOI: 10.3322/caac.20107.
3. Prayongrat A., Chakkabat C., Kannarunimit D. et al. Prevalence and significance of plasma Epstein–Barr Virus DNA level in nasopharyngeal carcinoma. J Radiat Res 2017;58(4):509–16. DOI: 10.1093/jrr/rrw128.
4. Zhang W., Chen Y., Chen L. et al. The clinical utility of plasma Epstein–Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) 2015;94(20):e845. DOI: 10.1097/MD.0000000000000845.
5. Chan J.Y., Wong S.T. The role of plasma Epstein–Barr virus in the management of recurrent nasopharyngeal carcinoma. Laryngoscope 2014;124(1):126–30. DOI: 10.1002/lary.24193.
6. Ferrari D., Codeca C., Bertuzzi C. et al. Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a western population. BMC Cancer 2012;12:208. DOI: 10.1186/1471-2407-12-208.
7. Hsu C.L., Chang K.P., Lin C.Y. et al. Plasma Epstein–Barr virus DNA concentration and clearance rate as a novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck 2012;34(8):1064–70. DOI: 10.1002/hed.21890.
8. Zhang J., Shu C., Song Y. et al. Epstein– Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis. Medicine (Baltimore) 2016;95(40):e5130. DOI: 10.1097/MD.0000000000005130.
9. Hou X., Zhao C., Guo Y. et al. Different clinical significance of pre- and posttreatment plasma Epstein–Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol) 2011;23(2):128–33. DOI: 10.1016/j.clon.2010.09.001.
10. World Health Organization Pathology and genetics head and neck tumors. Ed. by L. Barnes, J.W. Eveson, P. Reichart, D. Sidransky. Lyon, 2005. Pp. 81–106.
11. He S.S., Wang Y., Bao Y. et al. Dynamic changes in plasma Epstein–Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study. Cancer Med 2018;7(4):1110–7. DOI: 10.1002/cam4.1381.
12. Lu L., Li J., Zhao C. et al. Prognostic efficacy of combining tumor volume with Epstein–Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma. Oral Oncol 2016;60:18–24. DOI: 10.1016/j.oraloncology.2016.06.013.
13. Lam J.W., Chan J.Y., Ho W.K. et al. Use of transoral nasopharyngeal brush biopsy for Epstein–Barr virus DNA detection of local recurrence of nasopharyngeal carcinoma after radiotherapy. Head Neck 2016;38 Suppl 1:E1301–4. DOI: 10.1002/hed.24216.
14. Pow E.H., Law M.Y., Tsang P.C. et al. Salivary Epstein–Barr virus DNA level in patients with nasopharyngeal carcinoma following radiotherapy. Oral Oncol 2011;47(9):879–82. DOI: 10.1016/j.oraloncology.2011.06.507.
15. Leung S.F., Chan K.C., Ma B.B. et al. Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma Ann Oncol 2014;25(6):1204–8. DOI: 10.1093/annonc/mdu117.
16. Wang W.Y., Twu C.W., Chen H.H. et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16(3):1016–24. DOI: 10.1158/1078-0432.CCR-09-2796.
17. Chang K.P., Chang Y.T., Wu C.C. et al. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 2011;33(6):886–97. DOI: 10.1002/hed.21557.
18. Jin Y., Cai X.Y., Cai Y.C. et al. To build a prognostic score model containing indispensible tumor markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer 2012;48(6):882–8. DOI: 10.1016/j.ejca.2011.09.004.
Review
For citations:
Miroshnichenko D.A., Polyakov A.P., Mordovsky A.V. Monitoring the efficacy of conservative treatment of nasopharyngeal carcinoma by examining Epstein–Barr virus DNA titers in blood plasma (review). Head and Neck Tumors (HNT). 2020;10(3):81-89. (In Russ.) https://doi.org/10.17650/2222-1468-2020-10-3-81-89
Views:
697
Email this article 